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ABSTRACT
Objectives To compare costs associated with different 
models of outpatient parenteral antimicrobial therapy 
(OPAT) delivery with costs of inpatient (IP) care across key 
infection groups managed via OPAT in the UK.
Design A cost- minimisation design was used due to 
evidence of similarities in patient and treatment outcomes 
between OPAT and IP care. A bottom- up approach was 
undertaken for the evaluation of OPAT associated costs. 
The British Society of Antimicrobial Chemotherapy National 
Outcomes Registry System was used to determine key 
infection diagnoses, mean duration of treatment and most 
frequent antibiotics used.
Setting Several OPAT delivery settings were considered 
and compared with IP care.
Interventions OPAT models considered were OP clinic 
model, nurse home visits, self (or carer)- administration by 
a bolus intravenous, self- administration by a commercially 
prefilled elastomeric device, continuous intravenous 
infusion of piperacillin with tazobactam or flucloxacillin 
with elastomeric device as OP once daily and, specifically 
for bone and joint and diabetic foot infections, complex 
outpatient oral antibiotic therapies.
Results Base case and a range of scenario results 
showed all evaluated OPAT service delivery models to be 
less costly than IP stay of equivalent duration. The extent 
of savings varied by OPAT healthcare delivery models. 
Estimated OPAT costs as a proportion of IP costs were 
estimated at 0.23–0.53 (skin and soft- tissue infections), 
0.34–0.46 (complex urinary tract infections), 0.23–0.51 
(orthopaedic infections), 0.24–0.42 (diabetic foot 
infections) 0.40–0.56 (exacerbations of bronchiectasis) 
and 0.25–0.42 (intra- abdominal infections). Partial or full 
complex oral antibiotic therapies in orthopaedic or diabetic 
foot infections costs were estimated to be 0.13–0.26 of 
IP costs. Main OPAT costs were associated with staff time 
and antimicrobial medications.
Conclusions OPAT is a cost- effective use of National 
Health Service resources for the treatment of a range of 
infections in the UK in patients who can be safely managed 
in a non- IP setting.
INTRODUCTION
Outpatient parenteral antimicrobial therapy 
(OPAT) is a well- established and safe method 
of delivering intravenous antimicrobial 
therapy to carefully selected patients in 
whom other aspects of care can be addressed 
without hospitalisation.1 2 The British Society 
for Antimicrobial Chemotherapy (BSAC) has 
developed good practice recommendations 
for safe adult and paediatric OPAT practice 
and clinical governance including promotion 
of antimicrobial stewardship.2 The recom-
mendations acknowledged that a variety of 
OPAT delivery models were available and 
widely practised in the UK including home 
or clinic administration, administration by 
nurse or self/carer and administration via 
bolus or infusion. In 2015, BSAC launched 
the National Outcomes Registry System 
(NORS) for UK OPAT services in order to 
describe the OPAT landscape (including 
infections treated and antimicrobials used) 
and to enable participating centres to bench-
mark practice and outcomes.3 Despite popu-
larity and growth in OPAT practice in the UK, 
funding/reimbursement of OPAT has been 
inconsistent and as a result OPAT has not been 
uniformly established. A previous publica-
tion attempted to describe cost- effectiveness 
of OPAT in a tariff based UK health model 
Strengths and limitations of this study
 ► First study to use a bottom- up costing approach 
applied across a range of infections and healthcare 
delivery models in outpatient parenteral antimicro-
bial therapy (OPAT) using UK- specific registry data.
 ► First study to compare the cost of various models of 
care in OPAT with inpatient stay.
 ► Base case results were consistent across a range of 
scenario analyses.
 ► Assumed equivalence in OPAT and inpatient out-
comes and between different OPAT models of care 
is associated with some uncertainty.
 ► There are uncertainties in the quantification of some 
indirect OPAT costs (and their contribution to each 
OPAT model) and with inpatient bed day costs stay.
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for a single condition (cellulitis).4 Herein, we estimate 
OPAT- related costs for a number of key indicator condi-
tions utilising different established OPAT delivery models 
and compare with reference inpatient costs. The analysis 
also set out to take into account evolution of practice with 
greater use of supervised complex oral antibiotic thera-
pies within the OPAT setting.5
METHODS
The costs of six OPAT healthcare delivery models were 
estimated and compared against the cost of equivalent 
duration of inpatient stay for six key infection catego-
ries typically managed via OPAT in the UK. Based on 
available clinical evidence and clinical expert opinion, 
equivalence in patient outcomes was assumed for OPAT 
and inpatient stay as well as for the different models of 
healthcare delivery in OPAT.6–8 A cost- minimisation anal-
ysis was therefore deemed appropriate. A list of detailed 
costing model assumptions primarily based on the BSAC 
updated good practice recommendations2 and clinical 
expert opinion is available in online supplemental mate-
rials (online supplemental table 1.
NORS data
The cost- minimisation analysis used 5 years of retrospec-
tive data relating to 21 632 adult treatment episodes 
collected from 57 OPAT centres (44 in England, 5 in 
Scotland, 4 in Wales and 4 in Northern Ireland), that all 
reported to NORS3 (table 1). In the cost- minimisation 
model, patients were treated in OPAT for one of six 
broadly defined infection categories, representing 
approximately 82% of primary OPAT diagnoses recorded 
in NORS. These were infections requiring short- term (up 
to 7 days) antimicrobial treatment such as skin and soft- 
tissue infections including cellulitis (SSTI) and complex 
urinary tract infections (UTI) (including drug- resistant 
lower UTI and pyelonephritis) or longer- term antimi-
crobial treatment such as bone and joint (including 
spinal, native osteomyelitis and orthopaedic metal work 
associated infections), diabetic foot infections (both 
osteomyelitis and complex soft- tissue infections), bron-
chiectasis and intra- abdominal infections (including 
liver abscess and other abdominal and pelvic infections) 
(online supplemental table 2).
OPAT healthcare delivery models
The OPAT models considered were based on those 
currently practised in the UK: outpatient clinic model, 
nurse home visits, self (or carer)- administration by a 
bolus intravenous, self- administration via an elastomeric 
device including continuous intravenous infusion (CIVI) 
of piperacillin with tazobactam or flucloxacillin and 
(for bone and joint or diabetic foot infections) complex 
outpatient antibiotic therapy. Only suitable healthcare 
models were considered for the treatment of each of the 
six conditions in OPAT.
The care pathway for the outpatient clinic model 
requires a patient to travel daily to the OPAT unit following 
an initial assessment in hospital. At the clinic, an OPAT 
nurse prepares and administers antimicrobial medication 
intravenously by bolus intravenous. The nurse home visit 
model entails a specialist nurse (or a community- based 
nurse) travelling to the patient’s home instead.
The self- administration model of OPAT care requires 
the patient (or carer) to administer the antimicrobials 
at home, without the need to travel to hospital or for a 
nurse to visit on a daily basis. It is assumed that prior to 
commencing antimicrobial self- administration, patients 
(or their carers) receive on average three training 
sessions (60 min each with a nurse) on how to safely 
prepare and administer their medication through a 
peripherally inserted central catheter (PICC) line using 
a bolus intravenous. It is further assumed that only one 
training session is required for patient/carer adminis-
tration of preprepared medication via an elastomeric 
home infusion device which only needs to be connected 
to and disconnected from the PICC line correctly. The 
patient is discharged with the necessary consumables (eg, 
a leaflet of instructions, syringes, needles, 70% alcohol 
wipes, 0.9% sodium chloride ampoules, sharps bin, vials 
with medication powder for infusion, etc) and is given 
a contact number related to the OPAT service for use if 
any problems occur out of hours. On the occasion where 
an elastomeric pump is used for self- administration, these 
are commercially prefilled devices due to safety issues 
regarding the process of reconstituting drugs into elas-
tomeric devices outside of an aseptic unit and the associ-
ated reduction in shelf life (approximately 24 hours). A 
CIVI model of service delivery in OPAT involves reconsti-
tution of drugs into elastomeric devices by hospital staff 
with piperacillin with tazobactam or flucloxacillin on the 
same day of administration with the patient visiting clinic 
once daily.9 10
Patients referred to OPAT with bone and joint infec-
tions (eg, diabetic foot and orthopaedic infections) are 
increasingly considered for suitability for discharge on 
supervised complex oral therapies as an alternative to 
‘traditional’ OPAT intravenous therapy. Suitable patients 
Table 1 Average duration and total number of treatment 




(days) Total no Source
SSTI 6.4 7371 NORS 2015–19 
(UK)3Complex UTI 7.0 1896
Bone- Joint 27.8 5355
Diabetic foot 28.3 1797
Bronchiectasis 11.0 4096
Intra- abdominal 22.2 1117
NORS, national outcomes registry system; OPAT, outpatient 
parenteral antimicrobial therapy; SSTI, skin and soft- tissue 
infections; UTI, urinary tract infections.
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may be commenced directly onto supervised oral antimi-
crobial treatment which frequently requires enhanced 
monitoring due to potentially serious adverse events (eg, 
linezolid or combination oral antibiotic regimens).5
In all OPAT models where treatment is required 
for >1 week patients will also attend the OPAT clinic once 
weekly as a minimum and management/progress will be 
reviewed via a weekly virtual multidisciplinary meeting.2
Antimicrobials
Antimicrobial medications with a lower frequency of 
administration compared with inpatient care are primarily 
selected for use in OPAT. In the analysis, the type and 
distribution of antimicrobial medicines are based on clin-
ical expert opinion and the most prevalent agents used 
within the NORS database (online supplemental table 3).
Antimicrobial medicines which require more than 
once daily administration (eg, piperacillin with tazo-
bactam, flucloxacillin, temocillin, ceftazidime and mero-
penem) would be primarily administered by the patient 
or carer. However, if an antibiotic is stable to degradation 
in the outpatient setting (piperacillin with tazobactam 
and flucloxacillin), patients may receive the antibiotic via 
a 24- hour continuous infusion (CIVI) via an elastomeric 
device as an outpatient requiring once daily attendance. 
All other antimicrobial medicines where data on stability 
are either not available or are not compatible with 24- hour 
infusion may be administered with bolus intravenous or 
30 min intravenous infusion.
Rehospitalisation
The cost- minimisation model assumed hospital readmis-
sion to occur in 6.4% of treatment episodes in OPAT.7 
Rehospitalised patients were assumed to only spend 50% 
of the duration of their treatment episode in OPAT.
Costs
Costs considered in the analysis included specialist staff 
time (specialist nurses, infectious diseases consultant and 
specialist antimicrobial/clinical pharmacist), antimicro-
bial medications, elastomeric infusion devices (empty or 
commercially prefilled), consumables, laboratory tests 
and the cost of travel to and from the OPAT clinic where 
necessary (online supplemental tables 4–6). Additionally, 
costs of rehospitalisation for patients in OPAT have been 
included. A daily ‘overhead’ cost per patient to account 
for administration and support costs of using a healthcare 
service consistent with published literature has also been 
assumed in the analysis.8
Costs were obtained from various sources. These 
included the Personal and Social Services Research 
Unit,11 British National Formulary (BNF),12 drugs and 
pharmaceutical electronic market information tool 
(eMIT),13 National Procurement Scotland, Information 
Services Division (ISD) Scotland cost book14 and National 
Health Service (NHS) England reference costs.15
An appropriate healthcare resource group code15 
was identified for each diagnosis to account for costs of 
inpatient care (online supplemental table 7). Costs were 
based on a weighted average of excess bed day costs as 
elective and non- elective inpatient stay across various 
severity levels. No potential additional hospital costs were 
included.
Patient and public involvement
No patient involved.
RESULTS
Base case results from the cost- minimisation analysis 
are presented as estimated average cost per treatment 
episode in inpatient care and models of OPAT health-
care delivery, as well as cost of OPAT as a percentage of 
the estimated cost of inpatient stay (tables 2 and 3). Total 
costs of models of care and savings associated with OPAT 
across all conditions included within the NORS data set 
are shown in online supplemental table 8.
Infections requiring short-term treatment
Skin and soft-tissue infections
In the cost- minimisation analysis, patients attending once 
daily for the duration of antimicrobial treatment, were 
primarily treated with intravenous ceftriaxone, but also 
with teicoplanin and daptomycin (for beta- lactam allergy). 
Treatment with the same medicines was assumed in the 
specialist nurse visit model. A small number of patients 
could also be treated with dalbavancin 1 g as a one- off 
dose, consistent with clinical practice for patients unable 
to attend for daily treatment. Patients who were offered an 
elastomeric home infusion device were primarily treated 
with ceftriaxone once daily and less often with flucloxa-
cillin as 24 hours (CIVI). Dependant on the OPAT service 
delivery model, the cost of treating patients with SSTI was 
estimated in the range of 23%–51% of the cost of inpa-
tient stay for the equivalent duration of treatment.
Complex UTIs
In the analysis, patients were primarily treated with ertap-
enem (90%) and a minority of patients were treated with 
temocillin. It was assumed that patients attending daily 
or treated by a nurse at home were only given ertapenem 
due to twice daily dosing of temocillin. Both antibiotics 
can be self- administered using either short infusion or 
intravenous bolus, respectively. No patients were assumed 
to be treated using home infusion elastomeric devices. 
Dependant on the OPAT service delivery model, the cost 
of treating patients with complex UTI was estimated in 
the range of 34%–46% of the cost of inpatient stay for the 
equivalent duration of treatment.
Infections requiring longer-term treatment
Orthopaedic infections
Patients with orthopaedic infections were assumed to be 
treated once daily with ceftriaxone, teicoplanin or ertap-
enem in the outpatient visit, nurse home visit and self- 
administration OPAT service delivery models. Ceftriaxone 
was the only antimicrobial used for self- administration via 
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commercially prefilled elastomeric device. An analysis 
is also presented where patients were treated with oral 
therapies only or assuming intravenous to oral switch 
at different time points during supervised outpatient 
therapy. Dependant on the OPAT service delivery model 
(excluding oral therapies), the cost of treating patients 
with orthopaedic infections was estimated in the range of 
22%–41% of the cost of inpatient stay for the equivalent 
duration of treatment. Additionally, a movement in treat-
ment practice from intravenous to oral antibiotics could 
results in treatment cost of 13%–24% of the cost of inpa-
tient stay, dependent on how early a patient is switched to 
oral therapy.
Diabetic foot infections
Similarly to orthopaedic infections, patients with diabetic 
foot infections were assumed to be treated with ceftri-
axone, ertapenem and teicoplanin, although the propor-
tion of patients treated with each agent varied. All 
antimicrobial medicines are suitable for once daily admin-
istrations. The cost of treatment in OPAT was estimated in 
the range of 22%–42% of the cost of inpatient stay for the 
equivalent duration of treatment. Additionally, a move-
ment in treatment practice from intravenous to oral anti-
biotics could results in treatment cost of 13%–26% of the 
cost of inpatient stay, dependent on how early a patient is 
switched to oral therapy.
Bronchiectasis
In the analysis, patients were assumed to be treated with 
either ceftazidime, meropenem or piperacillin with tazo-
bactam. All medications are suitable for intravenous self- 
administration with either a bolus or 30 min infusion. 
Only piperacillin with tazobactam was assumed to be 
administered with an elastomeric device via a 24- hour 
continuous infusion in an outpatient setting (CIVI). 
The per- episode estimated cost for the same treatment 
plan with a visiting nurse is also presented. Since all of 
these medications require more than once daily admin-
istration or continuous daily administration, the general 
outpatient daily visits and nurse home visits OPAT service 
models are highly unlikely to be used in clinical practice 
so the results from CIVI models are presented instead. 
The estimated per treatment episode cost is in the range 
of 40%–56% of the cost of inpatient stay and varies with 
selected OPAT model of care.
Intra-abdominal infections
In the cost- minimisation analysis, patients were primarily 
treated with ertapenem or piperacillin with tazobactam. 
The latter was assumed to be used only in patients who 
were suitable for self- administration or attend daily for 
change of elastomeric device (CIVI). Patients who visit 
daily for intravenous infusions or receive nurse visits 
were assumed to only be treated with ertapenem. The 
estimated per treatment episode cost is in the range of 
25%–42% of the cost of inpatient stay and varies with 
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Scenario analyses
In scenario analyses described in table 4, certain model-
ling assumptions were challenged to assess impact on 
results in the outpatient setting model. Detailed scenario 
analysis results are provided in online supplemental table 
9.
Results from scenarios 1 and 2 (costs ranging between 
21% and 34% of inpatient costs) are consistent, although 
lower than base case (25%–44%) across all infection cate-
gories due to the higher cost per bed day generally associ-
ated with an infectious disease unit (IDU).
Given the modelling approach, one of the uncertain-
ties comes from the extent of model- specific per- patient 
overhead costs (scenario 3). The uncertainty is especially 
relevant to the outpatient clinic model. One study16 
reported overall overhead and support costs in the 
outpatient department of their IDU to be 44.8% of total 
costs excluding re- hospitalisation. When the equivalent 
assumption was made in the outpatient clinic model, the 
cost of treatment episode in OPAT did not increase over 
52% of the cost of inpatient stay, except for bronchiectasis 
(77%) which is treated with CIVI with elastomeric device 
as an outpatient visit once daily in the analysis which is 
generally associated with higher cost.
There are uncertainties around the source of cost 
for linezolid for the oral treatment of orthopaedic and 
diabetic foot infections (scenario 4). The cost reported 
in the BNF12 is substantially higher than what clinicians 
have advised and also reported in the eMIT13 which has 
been used in the base case analysis. Using the higher cost 
of linezolid results in the cost of oral therapies increasing 
from 13% to 21% of the cost of inpatient stay.
Additionally, variations in the treatment protocol with 
dalbavancin seems to have the highest impact on costs 
of treatment of SSTIs in OPAT due to the high medi-
cine acquisition cost (scenarios 6 and 7). Treatment with 
dalbavancin can be as costly as 74%–76% of the cost of 
inpatient stay.
DISCUSSION
Although OPAT has been developing in the UK over the 
last 25 years, and despite the clinical benefits of avoiding 
hospitalisation and keeping care closer to home, there 
Table 4 Scenarios: OPAT outpatient versus inpatient stay
Scenario Base case
0 Base case (outpatient)
1 Using cost of inpatient care in infectious disease unit 
(ISD Scotland)14
Using condition- specific healthcare resource group costs15
2 Using ISD Scotland14 cost for outpatient appointments 
and inpatient stay (IDU)
Using microcosting of nurse and consultant outpatient 
appointments
3 Assuming overheads are 44.8% of total costs 
consistent with a published source16
Assuming per day cost of using healthcare services consistent 
with a published source8
4 Using BNF12 as a source for the cost of linezolid 
(orthopaedic and diabetic foot infections)
Using eMIT13 as a source for the cost of linezolid (orthopaedic 
and diabetic foot infections)
Skin and soft- tissue infections only
5 Including the cost of consultant time Nurse- led condition; no consultant time
6 Using the licensed dose of dalbavancin (1.5 g) once off Using dalbavancin 1 g as a once- off treatment consistent with 
clinical practice
7 Using the licensed dose of dalbavancin 1 g followed by 
0.5 g
Using dalbavancin 1 g as a once- off treatment consistent with 
clinical practice
BNF, British National Formulary; eMIT, electronic market information tool; IDU, infectious disease unit; ISD, information services division; 
OPAT, outpatient parenteral antimicrobial therapy.
Table 3 Base case results—oral antimicrobials for orthopaedic and diabetic foot infections
Condition
Orthopaedic/bone and joint Diabetic footModel of care
Inpatient stay £8279 £8428
OPAT—oral 100% £1114 13% £1089 13%
OPAT—oral 25%; 75% IV £2009 24% £2161 26%
OPAT—oral 50%; 50% IV £1710 21% £1816 22%
OPAT—oral 75%; 25% IV £1410 17% £1470 17%
IV, intravenous; OPAT, outpatient parenteral antimicrobial therapies.
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remains wide variation in OPAT availability and inconsis-
tency in funding/commissioning of services in the UK. It 
is possible that OPAT may be perceived as an additional 
healthcare cost and this could be a significant barrier to 
more systematic support for service development. This 
study therefore set out to systematically detail OPAT costs 
and compare with inpatient costs for key OPAT- treated 
conditions. To our knowledge, a detailed costing of 
various OPAT healthcare delivery models in a UK setting 
has not been published before. Nevertheless, results are 
consistent with previous studies where overall cost of 
OPAT have been reported and/or compared with the cost 
of inpatient care.6 16–18 Key findings are that the self (or 
care)- administration model of care was associated with 
the lowest cost and nurse home visits generally had the 
highest estimated cost per treatment episode across all 
conditions evaluated. From all available OPAT models for 
patients with SSTIs, treatment with a single dose of dalba-
vancin was estimated to have the highest cost. However, 
only a small proportion of patients (an estimated 5%) are 
expected to be treated with dalbavancin in clinical prac-
tice. As expected, oral therapies were the lowest cost treat-
ment option for patients with orthopaedic (bone and 
joint) or diabetic foot infection. If patients are switched 
from intravenous as outpatient to oral therapies at least 
half way through their treatment duration, the results 
show the cost of treatment episode to be lower than the 
cost of self- administering intravenous antimicrobials for 
the whole treatment duration.
The cost- minimisation analysis found all OPAT service 
delivery models to be consistently associated with lower 
cost than inpatient stay of equivalent duration across a 
range of conditions in the UK NHS. The analysis shows 
the potential of OPAT to provide quality healthcare for 
suitable patients in an outpatient setting at a fraction of 
the cost of inpatient care. When the four most frequently 
used OPAT models of care (outpatient clinic, nurse 
home visit self (carer)- administration (bolus intravenous 
or elastomeric device) are considered individually, using 
NORS UK data,3 the 5 year estimated savings to the UK 
NHS associated with treatment in OPAT was found to 
be in the range of £60–77 million (online supplemental 
table 9). It should be noted that these data only relate to 
57 OPAT services and many have not contributed data 
consistently for all 5 years (data not shown). The esti-
mated cost savings to the NHS through systematic roll out 
of OPAT therefore is likely to be considerably higher.
Strengths of the presented analysis include a 
bottom- up costing approach applied across a range 
of infections, and healthcare delivery models in OPAT 
using UK- specific registry data. Furthermore, each of 
these estimated costs were compared against the cost of 
inpatient care in a UK setting and a comprehensive list 
of scenario analyses showed consistency with base case 
findings. However, the study also had some limitations. 
The assumption of equivalence in patient and treatment 
outcomes for OPAT and inpatient care as well as among 
various models of care in OPAT is based on published 
systematic reviews6–8 but direct comparative evidence is 
lacking. Furthermore, there was one study8 to suggest 
that a specialist nurse visit model is generally associated 
with better outcomes compared with other healthcare 
delivery models in OPAT. A published source was used 
for the cost of inpatient stay which is inconsistent with 
the bottom- up costing approach undertaken for the cost 
of OPAT.15 The assumption of cost of bed day in the anal-
ysis to be equivalent to the cost of excess bed days, as 
reported in NHS England Reference costs,15 is also asso-
ciated with uncertainties due to the structure of the reim-
bursement system in NHS England (eg, the presence of 
trim points). Nevertheless, this is considered to be the 
most suitable published source of costs of inpatient stay 
as it provides cost estimates for each of the six infection 
categories in the analysis. Lastly, the estimated average 
costs per treatment episode in OPAT aim to reflect 
existing OPAT services and thus set- up and implementa-
tion costs have not been included.
It is important to note that most OPAT services will not 
rely on one particular delivery model and that individual 
patient factors such as, ability to self- administer or to 
attend the OPAT clinic, and choice of antimicrobial, will 
be the major determinants of the delivery model used. 
The data presented necessarily incorporate multiple vari-
ables to allow for variation based on patient need.
OPAT is primarily about delivering high quality patient 
centred care closer to home while avoiding inherent risks 
associated with hospitalisation. These positive health 
economic findings should be utilised by OPAT clinician/
practitioners, healthcare managers and policy makers 
alongside the already powerful clinical effectiveness and 
patient safety data to drive further OPAT development in 
the UK.
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